BACKGROUND: Improved control efforts are reducing the burden of malaria in Africa but may result in decreased antimalarial immunity. METHODS: A cohort of 129 children aged 1-10 years in Kampala, Uganda, were treated withamodiaquine plus sulfadoxine-pyrimethamine for 396 episodes of uncomplicated malaria over a 29-month period as part of a longitudinal clinical trial. RESULTS: The risk of treatment failure increased over the course of the study from 5% to 21% (hazard ratio [HR], 2.4 per year [95% confidence interval {CI}, 1.3-4.3]). Parasite genetic polymorphisms were associated with an increased risk of failure, but their prevalence did not change over time. Three markers of antimalarial immunity were associated with a decreased risk of treatment failure: increased age (HR, 0.5 per 5-year increase [95% CI, 0.2-1.2]), living in an area of higher malaria incidence (HR, 0.26 [95% CI, 0.11-0.64]), and recent asymptomatic parasitemia (HR, 0.06 [95% CI, 0.01-0.36]). In multivariate analysis, adjustment for recent asymptomatic parasitemia, but not parasite polymorphisms, removed the association between calendar time and the risk of treatment failure (HR, 1.5 per year [95% CI, 0.7-3.4]), suggesting that worsening treatment efficacy was best explained by decreasing host immunity. CONCLUSION: Declining immunity in our study population appeared to be the primary factor underlying decreased efficacy of amodiaquine plus sulfadoxine-pyrimethamine. With improved malaria-control efforts, decreasing immunity may unmask resistance to partially efficacious drugs.
RCT Entities:
BACKGROUND: Improved control efforts are reducing the burden of malaria in Africa but may result in decreased antimalarial immunity. METHODS: A cohort of 129 children aged 1-10 years in Kampala, Uganda, were treated with amodiaquine plus sulfadoxine-pyrimethamine for 396 episodes of uncomplicated malaria over a 29-month period as part of a longitudinal clinical trial. RESULTS: The risk of treatment failure increased over the course of the study from 5% to 21% (hazard ratio [HR], 2.4 per year [95% confidence interval {CI}, 1.3-4.3]). Parasite genetic polymorphisms were associated with an increased risk of failure, but their prevalence did not change over time. Three markers of antimalarial immunity were associated with a decreased risk of treatment failure: increased age (HR, 0.5 per 5-year increase [95% CI, 0.2-1.2]), living in an area of higher malaria incidence (HR, 0.26 [95% CI, 0.11-0.64]), and recent asymptomatic parasitemia (HR, 0.06 [95% CI, 0.01-0.36]). In multivariate analysis, adjustment for recent asymptomatic parasitemia, but not parasite polymorphisms, removed the association between calendar time and the risk of treatment failure (HR, 1.5 per year [95% CI, 0.7-3.4]), suggesting that worsening treatment efficacy was best explained by decreasing host immunity. CONCLUSION: Declining immunity in our study population appeared to be the primary factor underlying decreased efficacy of amodiaquine plus sulfadoxine-pyrimethamine. With improved malaria-control efforts, decreasing immunity may unmask resistance to partially efficacious drugs.
Authors: James G Kublin; Fraction K Dzinjalamala; Deborah D Kamwendo; Elissa M Malkin; Joseph F Cortese; Lisa M Martino; Rabia A G Mukadam; Stephen J Rogerson; Andres G Lescano; Malcolm E Molyneux; Peter A Winstanley; Phillips Chimpeni; Terrie E Taylor; Christopher V Plowe Journal: J Infect Dis Date: 2002-01-17 Impact factor: 5.226
Authors: C H Sibley; J E Hyde; P F Sims; C V Plowe; J G Kublin; E K Mberu; A F Cowman; P A Winstanley; W M Watkins; A M Nzila Journal: Trends Parasitol Date: 2001-12
Authors: G Dorsey; M R Kamya; G Ndeezi; J N Babirye; C R Phares; J E Olson; E T Katabira; P J Rosenthal Journal: Am J Trop Med Hyg Date: 2000-06 Impact factor: 2.345
Authors: Sarah G Staedke; Hakim Sendagire; Steven Lamola; Moses R Kamya; Grant Dorsey; Philip J Rosenthal Journal: Trop Med Int Health Date: 2004-05 Impact factor: 2.622
Authors: Abdoulaye A Djimdé; Ogobara K Doumbo; Ousmane Traore; Ando B Guindo; Kassoum Kayentao; Yacouba Diourte; Safiatou Niare-Doumbo; Drissa Coulibaly; Abdoulaye K Kone; Yacouba Cissoko; Mamadou Tekete; Bakary Fofana; Alassane Dicko; Dapa A Diallo; Thomas E Wellems; Dominic Kwiatkowski; Christopher V Plowe Journal: Am J Trop Med Hyg Date: 2003-11 Impact factor: 2.345
Authors: Daniel Kyabayinze; Adithya Cattamanchi; Moses R Kamya; Philip J Rosenthal; Grant Dorsey Journal: Am J Trop Med Hyg Date: 2003-09 Impact factor: 2.345
Authors: Bryan Greenhouse; Benjamin Ho; Alan Hubbard; Denise Njama-Meya; David L Narum; David E Lanar; Sheetij Dutta; Philip J Rosenthal; Grant Dorsey; Chandy C John Journal: J Infect Dis Date: 2011-07-01 Impact factor: 5.226
Authors: Ann M Moormann; Peter Odada Sumba; Kiprotich Chelimo; Hua Fang; Daniel J Tisch; Arlene E Dent; Chandy C John; Carole A Long; John Vulule; James W Kazura Journal: J Infect Dis Date: 2013-03-28 Impact factor: 5.226
Authors: Stephanie G Valderramos; Juan-Carlos Valderramos; Lise Musset; Lisa A Purcell; Odile Mercereau-Puijalon; Eric Legrand; David A Fidock Journal: PLoS Pathog Date: 2010-05-13 Impact factor: 6.823
Authors: Frederick N Baliraine; Yaw A Afrane; Dolphine A Amenya; Mariangela Bonizzoni; Anne M Vardo-Zalik; David M Menge; Andrew K Githeko; Guiyun Yan Journal: BMC Infect Dis Date: 2010-09-24 Impact factor: 3.090
Authors: Tamara D Clark; Denise Njama-Meya; Bridget Nzarubara; Catherine Maiteki-Sebuguzi; Bryan Greenhouse; Sarah G Staedke; Moses R Kamya; Grant Dorsey; Philip J Rosenthal Journal: PLoS One Date: 2010-07-30 Impact factor: 3.240
Authors: Chris E Keh; Aashish R Jha; Bridget Nzarubara; David E Lanar; Sheetij Dutta; Michael Theisen; Philip J Rosenthal; Grant Dorsey; Douglas F Nixon; Bryan Greenhouse Journal: PLoS One Date: 2012-12-19 Impact factor: 3.240
Authors: Natalie M Bowman; Seth Congdon; Tisungane Mvalo; Jaymin C Patel; Veronica Escamilla; Michael Emch; Francis Martinson; Irving Hoffman; Steven R Meshnick; Jonathan J Juliano Journal: Sci Rep Date: 2013 Impact factor: 4.379